Company Name, Ticker, Suppliers, else..

Decibel Therapeutics Inc (NASDAQ: DBTX)

Sector • Healthcare Industry • Major Pharmaceutical Preparations

Industry • Major Pharmaceutical Preparations

Sector • Healthcare

Decibel Therapeutics Inc 's

Name: Decibel Therapeutics Inc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

DBTX Sales vs. its Competitors Q2 2023

Comparing the current results to its competitors, Decibel Therapeutics Inc reported Revenue decrease in the 2 quarter 2023 year on year by 0 %, slower than the combined decrease of the DBTX's competitors by -3.72 %, recorded in the same quarter.

• List of DBTX Competitors

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

Decibel Therapeutics Inc , slower than the average decrease reported by the company's competitors of -8.47 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -8.47 %

<< DBTX Stock Performance Comparisons

<< See the full list of DBTX competitors

*Market share is calculated based on total revenue.

DBTX's Stock Performance relative to its Competitors

Publicly Traded Peers of Decibel Therapeutics Inc

Zevra Therapeutics Inc
Share Performance

-7.48%

30 Days

Zevra Therapeutics Inc

Profile

Zevra Therapeutics Inc operates on a business model that focuses on the development and commercialization of innovative therapeutics.

More about Zevra Therapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 683.290 mill.	$ 128.855 mill.	$ 57.904 mill.

Amgen Inc
Share Performance

+24.59%

This Year

Amgen Inc

Profile

Amgen Inc.s business model focuses on leveraging advanced biotechnology to create therapeutic products for various diseases, particularly in the fields of oncology, inflammation, and cardiovascular health. The company invests heavily in research and development to drive innovation, while also utilizing strategic partnerships and acquisitions to enhance its product pipeline. Additionally, Amgen emphasizes a strong global commercial presence to maximize the accessibility and impact of its therapeutics in the healthcare market.

More about Amgen Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 222,071.680 mill.	$ 38,095.000 mill.	$ 8,743.000 mill.

Allarity Therapeutics Inc
Share Performance

-22.56%

30 Days

Allarity Therapeutics Inc

Profile

Allarity Therapeutics Inc is a biotechnology company that leverages its unique drug response profiling platform to develop personalized cancer treatments. They use AI algorithms to match patients with the most effective therapies by analyzing their individual molecular profiles.

More about Allarity Therapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 16.388 mill.	$ - mill.	$ -12.334 mill.

Unity Biotechnology Inc
Share Performance

-86.01%

One Year

Unity Biotechnology Inc

Profile

Unity Biotechnology Inc. is a biotechnology company that focuses on developing therapies to treat age-related diseases. Their business model revolves around identifying and targeting specific senescent cells to address age-related conditions like osteoarthritis, kidney disease, and ophthalmic diseases. By leveraging their expertise in cellular senescence, Unity Biotechnology aims to develop innovative treatments that have the potential to extend healthy human lifespan.

More about Unity Biotechnology Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 3.376 mill.	$ - mill.	$ -27.502 mill.

2seventy Bio Inc
Share Performance

+0.81%

30 Days

2seventy Bio Inc

Profile

2seventy Bio Inc operates on a business model centered around the development and commercialization of innovative genetic therapies. They strive to harness the power of biotechnology to address complex diseases and improve patient outcomes. By advancing their proprietary gene delivery technologies and collaborating with industry partners, they aim to create scalable treatments that revolutionize the field of genetic medicine.

More about 2seventy Bio Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 267.165 mill.	$ 48.365 mill.	$ -4.092 mill.

55 more competitors available

Sources: Decibel Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Friday, September 18, 2026 5:33 PM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Decibel Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.